Blood lipid can help predict the graft function of living donor liver transplant recipients

According to a study published in the journal Liver Transplantation, measuring lipids after transplantation may help predict living donor liver transplant recipients graft regeneration and some plants dysfunction.

Liver transplant recipients with living donor liver transplantation (LDLT; different from non-living donor liver transplantation [DDLT]), the liver can regenerate quickly, sometimes partial graft dysfunction (SGD). "Liver regeneration requires a lot of re-synthesis of lipids, we previously reported, the expression of living donor liver transplantation abnormal lipid-related genes", outside the University of Pennsylvania, Dr. Kim M.Olthoff scientific and colleagues note that "now, we measure and compare a lipid levels 41 cases of living donor liver transplant recipients (LDLT) and 43 patients with non-living donor liver transplant recipients ([DDLT) baseline and after liver transplantation series of time points.

Study enrolled patients from the University of Pennsylvania genome and regenerative transplantation research, measuring their lipid levels to assess the living donor liver transplantation (LDLT) lipid / Apolipoprotein whether liver regeneration (use within 3 months of liver volume growth percentage [% VI] measurement) or partial graft dysfunction degree (segmental graft dysfunction, SGD) related.

The results showed that, compared to non-living donor liver transplantation (DDLT), the lipid levels declined in living donor liver transplantation (LDLT) in early stage. But 30 days later it restored to the same baseline lipid levels. Within 30 days of serum apolipoprotein increased by 1mg / dL, liver regeneration significantly (> 90% VI) OR = 2.53 (95% CI, 1.15-5.52); donor age growth per year SGD OR = 1.19 (95% CI, 1.15-5.52), 7 serum high-density lipoprotein days increased by 1mg / dL OR = 0.61 (95% CI, 0.34-1.11). Preoperative blood lipid/apolipoprotein in living donor liver transportation is not related to SGD or percentage (% VI) of expansive liver's volume.

The researchers concluded that the start-up of liver regeneration makes the liver not be able to participate fully in the lipid transportation and metabolism. If graft body cannot meet the metabolic demands, it may lead to liver dysfunction and some graft dysfunction (SGD).

Read more: http://www.cusabio.com/ELISA-Kit/Rat-Adrenocorticotropic-hormone-receptorMC2R-ELISA-kit-1081318.html